CN111886005B - 氟乙基去甲美金刚胺用于预防和治疗焦虑的用途 - Google Patents
氟乙基去甲美金刚胺用于预防和治疗焦虑的用途 Download PDFInfo
- Publication number
- CN111886005B CN111886005B CN201880089497.5A CN201880089497A CN111886005B CN 111886005 B CN111886005 B CN 111886005B CN 201880089497 A CN201880089497 A CN 201880089497A CN 111886005 B CN111886005 B CN 111886005B
- Authority
- CN
- China
- Prior art keywords
- anxiety
- treatment
- product
- pharmaceutically acceptable
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 96
- 238000011282 treatment Methods 0.000 title claims abstract description 77
- 230000036506 anxiety Effects 0.000 title claims abstract description 69
- 230000002265 prevention Effects 0.000 title claims description 10
- HUYVZSFADWYSHD-UHFFFAOYSA-N 3-(2-fluoroethyl)adamantan-1-amine Chemical compound C1C(C2)CC3CC1(N)CC2(CCF)C3 HUYVZSFADWYSHD-UHFFFAOYSA-N 0.000 title abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 230000001430 anti-depressive effect Effects 0.000 claims abstract description 13
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 9
- 229940005513 antidepressants Drugs 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 61
- 239000000047 product Substances 0.000 claims description 30
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 22
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 16
- 229960003299 ketamine Drugs 0.000 claims description 16
- 229960003712 propranolol Drugs 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 150000001450 anions Chemical class 0.000 claims description 4
- 239000013066 combination product Substances 0.000 claims description 4
- 229940127555 combination product Drugs 0.000 claims description 4
- -1 dibenzoate Chemical compound 0.000 claims description 4
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 206010034912 Phobia Diseases 0.000 claims description 3
- 229940072107 ascorbate Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 3
- 229940077388 benzenesulfonate Drugs 0.000 claims description 3
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 3
- 229960001860 salicylate Drugs 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 208000008811 Agoraphobia Diseases 0.000 claims description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 201000001716 specific phobia Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 230000001149 cognitive effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 64
- 238000012360 testing method Methods 0.000 description 45
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 42
- 241001465754 Metazoa Species 0.000 description 39
- 229960004640 memantine Drugs 0.000 description 39
- 238000010171 animal model Methods 0.000 description 25
- 230000000472 traumatic effect Effects 0.000 description 25
- 230000000949 anxiolytic effect Effects 0.000 description 21
- 230000003750 conditioning effect Effects 0.000 description 21
- 201000000980 schizophrenia Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 15
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 15
- 230000006399 behavior Effects 0.000 description 14
- 241000283984 Rodentia Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 11
- 239000002249 anxiolytic agent Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 238000011161 development Methods 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 230000015654 memory Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000005526 G1 to G0 transition Effects 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 6
- 206010063659 Aversion Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000009225 cognitive behavioral therapy Methods 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 229930195712 glutamate Natural products 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 238000011105 stabilization Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 208000032140 Sleepiness Diseases 0.000 description 5
- 206010041349 Somnolence Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229940049706 benzodiazepine Drugs 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 5
- 230000000698 schizophrenic effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 4
- 206010012239 Delusion Diseases 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010028347 Muscle twitching Diseases 0.000 description 4
- 208000028017 Psychotic disease Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000008451 emotion Effects 0.000 description 4
- 229960002464 fluoxetine Drugs 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 230000001739 rebound effect Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 231100000868 delusion Toxicity 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000036278 prepulse Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010029412 Nightmare Diseases 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 208000003217 Tetany Diseases 0.000 description 2
- 238000013542 behavioral therapy Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 238000009226 cognitive therapy Methods 0.000 description 2
- 231100000867 compulsive behavior Toxicity 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000014061 fear response Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- 230000001373 regressive effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- ABYZSYDGJGVCHS-ZETCQYMHSA-N (2s)-2-acetamido-n-(4-nitrophenyl)propanamide Chemical compound CC(=O)N[C@@H](C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 ABYZSYDGJGVCHS-ZETCQYMHSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010016754 Flashback Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000028517 Neuropeptide receptor Human genes 0.000 description 1
- 108070000018 Neuropeptide receptor Proteins 0.000 description 1
- 229940127307 Noncompetitive NMDA Receptor Antagonists Drugs 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010040108 Serotonin syndrome Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 235000004240 Triticum spelta Nutrition 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000006400 anxiety behaviour Effects 0.000 description 1
- 230000000338 anxiogenic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical class O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000000768 catecholaminergic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960005217 dapoxetine Drugs 0.000 description 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 230000006390 fear memory Effects 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000015930 mixed anxiety and depressive disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000010255 response to auditory stimulus Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960002263 vortioxetine Drugs 0.000 description 1
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 description 1
- 229960002791 zimeldine Drugs 0.000 description 1
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1762290 | 2017-12-15 | ||
FR1762290A FR3075038B1 (fr) | 2017-12-15 | 2017-12-15 | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
PCT/EP2018/085333 WO2019115833A1 (fr) | 2017-12-15 | 2018-12-17 | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111886005A CN111886005A (zh) | 2020-11-03 |
CN111886005B true CN111886005B (zh) | 2023-12-15 |
Family
ID=62091972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880089497.5A Active CN111886005B (zh) | 2017-12-15 | 2018-12-17 | 氟乙基去甲美金刚胺用于预防和治疗焦虑的用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11464751B2 (zh) |
EP (1) | EP3723742B1 (zh) |
JP (1) | JP7301871B2 (zh) |
CN (1) | CN111886005B (zh) |
CA (1) | CA3085585A1 (zh) |
ES (1) | ES2963655T3 (zh) |
FR (1) | FR3075038B1 (zh) |
WO (1) | WO2019115833A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020232246A1 (en) * | 2019-05-15 | 2020-11-19 | The Trustees Of Columbia University In The City Of New York | Compositions and methods against stress-induced affective disorders and their associated symptoms |
FR3110393B1 (fr) | 2020-05-20 | 2022-05-06 | Grn Consulting | Compose et composition pour induire une neuroprotection |
FR3128872A1 (fr) | 2021-11-08 | 2023-05-12 | Rest Therapeutics | Nouvelles combinaisons synergiques a base de fenm |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104902883A (zh) * | 2012-08-23 | 2015-09-09 | 斯图亚特·L·韦格 | 抗焦虑组合物、制剂及使用方法 |
US20160107982A1 (en) * | 2013-05-29 | 2016-04-21 | M2I Development | Novel chemical compounds derived from normemantine and use of same in the medical field |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0216555B1 (en) | 1985-09-11 | 1992-09-02 | Btg International Limited | Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections |
WO2006034465A1 (en) | 2004-09-23 | 2006-03-30 | Merz Pharma Gmbh & Co. Kgaa | Memantine for the treatment of childhood behavioral disorders |
JP4270287B2 (ja) | 2007-02-21 | 2009-05-27 | セイコーエプソン株式会社 | 液晶表示装置 |
US8008253B2 (en) | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
WO2014144546A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositons for improving cognitive function |
-
2017
- 2017-12-15 FR FR1762290A patent/FR3075038B1/fr active Active
-
2018
- 2018-12-17 WO PCT/EP2018/085333 patent/WO2019115833A1/fr unknown
- 2018-12-17 US US16/772,582 patent/US11464751B2/en active Active
- 2018-12-17 JP JP2020552138A patent/JP7301871B2/ja active Active
- 2018-12-17 ES ES18815771T patent/ES2963655T3/es active Active
- 2018-12-17 EP EP18815771.3A patent/EP3723742B1/fr active Active
- 2018-12-17 CA CA3085585A patent/CA3085585A1/fr active Pending
- 2018-12-17 CN CN201880089497.5A patent/CN111886005B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104902883A (zh) * | 2012-08-23 | 2015-09-09 | 斯图亚特·L·韦格 | 抗焦虑组合物、制剂及使用方法 |
US20160107982A1 (en) * | 2013-05-29 | 2016-04-21 | M2I Development | Novel chemical compounds derived from normemantine and use of same in the medical field |
Non-Patent Citations (1)
Title |
---|
Memantine as an augmentation therapy for anxiety disorders;Thomas L Schwartz等;《Case Reports in Psychiatry》;20120208;第2012卷;第749796页 * |
Also Published As
Publication number | Publication date |
---|---|
EP3723742A1 (fr) | 2020-10-21 |
FR3075038A1 (fr) | 2019-06-21 |
JP2021506963A (ja) | 2021-02-22 |
US20200383939A1 (en) | 2020-12-10 |
EP3723742C0 (fr) | 2023-08-30 |
JP7301871B2 (ja) | 2023-07-03 |
ES2963655T3 (es) | 2024-04-01 |
CN111886005A (zh) | 2020-11-03 |
US11464751B2 (en) | 2022-10-11 |
WO2019115833A1 (fr) | 2019-06-20 |
EP3723742B1 (fr) | 2023-08-30 |
CA3085585A1 (fr) | 2019-06-20 |
FR3075038B1 (fr) | 2020-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Planchez et al. | Animal models of major depression: drawbacks and challenges | |
Sarkisova et al. | Spike–wave discharges are necessary for the expression of behavioral depression‐like symptoms | |
Yazir et al. | Resveratrol exerts anti-inflammatory and neuroprotective effects to prevent memory deficits in rats exposed to chronic unpredictable mild stress | |
Fraga et al. | Anxiolytic effects of ascorbic acid and ketamine in mice | |
MD et al. | REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP | |
CN111886005B (zh) | 氟乙基去甲美金刚胺用于预防和治疗焦虑的用途 | |
Silva et al. | Prenatal tetrahydrocannabinol (THC) alters cognitive function and amphetamine response from weaning to adulthood in the rat | |
AU2017374777A1 (en) | Use of cannabidiol in the treatment of angelman syndrome | |
Abadi et al. | Effects of different exercise protocols on ethanol-induced spatial memory impairment in adult male rats | |
JP2018516906A (ja) | レベチラセタムの持続放出性医薬組成物 | |
EA037187B1 (ru) | Способ и композиция для лечения когнитивного расстройства | |
Kumar et al. | Tremor and rigidity in patients with Parkinson’s disease: Emphasis on epidemiology, pathophysiology and contributing factors | |
Kim et al. | Effects of high-frequency repetitive transcranial magnetic stimulation (rTMS) on spontaneously hypertensive rats, an animal model of attention-deficit/hyperactivity disorder | |
Lee et al. | Neuroprotective effect of Korean Red Ginseng against single prolonged stress-induced memory impairments and inflammation in the rat brain associated with BDNF expression | |
Haider et al. | Alleviation of diazepam-induced conditioned place preference and its withdrawal-associated neurobehavioral deficits following pre-exposure to enriched environment in rats | |
Beretta et al. | Rescuing epileptic and behavioral alterations in a Dravet syndrome mouse model by inhibiting eukaryotic elongation factor 2 kinase (eEF2K) | |
Sahini et al. | Environmental enrichment improves cognitive function, learning, memory and anxiety-related behaviours in rodent models of dementia: implications for future study | |
CN116916903A (zh) | 墨斯卡林和墨斯卡林类似物(scalines)辅助心理治疗的作用 | |
Carrasco et al. | Bupropion induced changes in exploratory and anxiety-like behaviour in NMRI male mice depends on the age | |
Scheggi et al. | Effects of the 5-HT6 receptor agonist ST 1936 on depression-and anhedonia-like experimental models | |
Martino et al. | Unvoluntary motor behaviours | |
Mishchenko et al. | Experimental research of cerebroprotective activity of the new 4-aminobutatanoic acid derivative | |
CN104936584B (zh) | 用于行为、精神和认知障碍的预防和治疗的组合物 | |
Ferreira | Characterization of the emotional fingerprint of METH intoxicated animals | |
Friar | Ketamine’s Effects on Adolescent Female Wistar-Kyoto and Wistar Rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210922 Address after: Fa Guomengbiliai Applicant after: Rester medical Address before: The French Saint Cloud Applicant before: Melchio investment and Industrial Co. Effective date of registration: 20210922 Address after: The French Saint Cloud Applicant after: Melchio investment and Industrial Co. Address before: Lacq Applicant before: Melchio materials and Life Sciences |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Paris France Applicant after: Rester medical Address before: Montpelier, France Applicant before: Rester medical |
|
GR01 | Patent grant | ||
GR01 | Patent grant |